MBRX vs. LPCN, CING, MTEX, GELS, CARM, MRKR, CTXR, RVPH, PMN, and GOVX
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), Gelteq (GELS), Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry.
Moleculin Biotech vs. Its Competitors
Lipocine (NASDAQ:LPCN) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.
Lipocine has higher revenue and earnings than Moleculin Biotech.
Lipocine has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
Lipocine's return on equity of -26.68% beat Moleculin Biotech's return on equity.
9.1% of Lipocine shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 1.9% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Moleculin Biotech had 3 more articles in the media than Lipocine. MarketBeat recorded 5 mentions for Moleculin Biotech and 2 mentions for Lipocine. Moleculin Biotech's average media sentiment score of 0.87 beat Lipocine's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.
Lipocine presently has a consensus target price of $9.00, indicating a potential upside of 171.08%. Moleculin Biotech has a consensus target price of $4.00, indicating a potential upside of 649.06%. Given Moleculin Biotech's higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than Lipocine.
Summary
Lipocine and Moleculin Biotech tied by winning 5 of the 10 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:MBRX) was last updated on 7/10/2025 by MarketBeat.com Staff
